We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

76 hedge funds and large institutions have $115M invested in Zynerba Pharmaceuticals, Inc in 2019 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

823% more capital invested

Capital invested by funds: $12.5M → $115M (+$103M)

214% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 7

106% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 17

25% more funds holding

Funds holding: 61 → 76 (+15)

15% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $10.5M

Holders
76
Holders Change
+15
Holders Change %
+24.59%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
22
Reduced
7
Closed
17
Calls
$12.1M
Puts
$10.5M
Net Calls
+$1.6M
Net Calls Change
+$2.53M

Top Buyers

Rank Fund Capital Flow
1
EMG
ETF Managers Group
New Jersey
+$25.8M
2
BlackRock
BlackRock
New York
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.98M
4
PCM
Portolan Capital Management
Massachusetts
+$7.24M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$4.67M

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.01M
2
CCM
Campbell Capital Management
Florida
-$958K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$824K
4
PP
PDT Partners
New York
-$476K
5
HighTower Advisors
HighTower Advisors
Illinois
-$364K
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
76
PDT Partners
New York
– -$476K -87,800 Closed
EGM
77
Engineers Gate Manager
New York
– -$294K -54,321 Closed
Squarepoint
78
Squarepoint
New York
– -$133K -24,453 Closed
SIM
79
Spark Investment Management
New York
– -$130K -24,100 Closed
VF
80
Virtu Financial
New York
– -$121K -22,384 Closed
ARTA
81
A.R.T. Advisors
New York
– -$100K -18,388 Closed
Goldman Sachs
82
Goldman Sachs
New York
– -$57K -10,495 Closed
Simplex Trading
83
Simplex Trading
Illinois
– -$23K -1,989 Closed
OC
84
Oakworth Capital
Alabama
– -$11K -1,965 Closed
PFO
85
Pathstone Family Office
New Jersey
– -$5K -1,000 Closed
SWM
86
SeaCrest Wealth Management
New York
– -$3K -510 Closed
FIA
87
FNY Investment Advisers
New York
– -$5.77K -500 Closed
FANJ
88
Financial Architects (New Jersey)
New Jersey
– -$2K -400 Closed
AIC
89
Ameritas Investment Company
Nebraska
– -$2K -309 Closed
NWM
90
Northwest Wealth Management
Iowa
– -$1K -200 Closed
WEC
91
Winslow Evans & Crocker
Massachusetts
– -$2K -50 Closed
1 2 3
4

ZYNE Hedge Fund Activity: Q2 2019 in Review

76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2019, worth a combined $115M — up 823% from $12.5M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ZYNE positions and 17 closed out — a net gain of 18 holders — while 22 added to existing stakes and 7 trimmed.

The largest buyer was ETF Managers Group, opening a new position worth an estimated $25.8M. The largest seller was Susquehanna International Group, cutting an estimated $1.01M.

  • 76 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2019, up from 61 in Q1 2019.
  • Funds reported $115M of Zynerba Pharmaceuticals, Inc stock for Q2 2019, up 823% quarter-over-quarter.
  • 35 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2019 and 17 closed out, a net change of +18 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2019 was ETF Managers Group, an estimated $25.8M added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q2 2019 was Susquehanna International Group, an estimated $1.01M sold.

Based on aggregated 13F filings for Q2 2019.